Literature DB >> 231420

A role of red cell pyrimidine 5'-nucleotidase in experimental lead poisoning.

H Fujii.   

Abstract

Intravenous administration of lead acetate to rabbits for 10 weeks at 2 week intervals resulted in significantly elevated blood lead levels, slight anemia with marked microspherocytosis and moderate basophilic stippling, and marked depression of red cell delta-aminolevulinic acid (ALA) dehydratase activity. However the decrease in red cell pyrimidine 5'-nucleotidase (P5N) activity was slight when compared to the red cell P5N activity of comparable reticulocyte-rich blood, and intracellular accumulation of pyrimidine nucleotides could not be demonstrated. In the in vitro inhibition test the same degree of inhibition of red cell P5N activity seen in hereditary red cell P5N deficiency was obtained by using a lead concentration 200--400 times higher than the lead levels detected in human plumbism. Most importantly, there were no differences in the lead-induced inhibition of human and rabbit red cell P5N. From the results of the in vitro inhibition test, lead-induced red cell P5N deficiency appears to be one of several pathogenic mechanisms in chronic lead exposure associated with the accumulation of lead in bone marrow. A decrease in rec cell P5N activity could not be demonstrated despite the marked depression in red cell ALA dehydratase activity, and slight anemia with marked microspherocytosis and moderate basophilic stippling in this experiment. These results suggest that lead affects red cells at multiple metabolic loci.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 231420     DOI: 10.1007/bf00695874

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  15 in total

Review 1.  Lead and the red cell.

Authors:  J M White; H S Selhi
Journal:  Br J Haematol       Date:  1975-06       Impact factor: 6.998

2.  Effects of low-level lead exposure on pyrimidine 5'-nucleotidase and other erythrocyte enzymes. Possible role of pyrimidine 5'-nucleotidase in the pathogenesis of lead-induced anemia.

Authors:  D E Paglia; W N Valentine; J G Dahlgren
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

3.  Characteristics of a pyrimidine-specific 5'-nucleotidase in human erythrocytes.

Authors:  D E Paglia; W N Valentine
Journal:  J Biol Chem       Date:  1975-10-25       Impact factor: 5.157

4.  The effect of lead on total globin and alpha- and beta-chain synthesis; in vitro and in vivo.

Authors:  S K Piddington; J M White
Journal:  Br J Haematol       Date:  1974-07       Impact factor: 6.998

5.  Delta-aminolevulinic acid dehydratase activity in erythrocytes for the evaluation of lead poisoning.

Authors:  K Nakao; O Wada; Y Yano
Journal:  Clin Chim Acta       Date:  1968-02       Impact factor: 3.786

Review 6.  Lead and hemopoiesis. The mechanism and consequences of the erythropathy of occupational lead poisoning.

Authors:  C Albahary
Journal:  Am J Med       Date:  1972-03       Impact factor: 4.965

7.  Red-cell pyrimidine 5'-nucleotidase and lead poisoning.

Authors:  H A Buc; J C Kaplan
Journal:  Clin Chim Acta       Date:  1978-07-01       Impact factor: 3.786

8.  Lead poisoning. Further observations on erythrocyte pyrimidine-nucleotidase deficiency and intracellular accumulation of pyrimidine nucleotides.

Authors:  D E Paglia; W N Valentine; K Fink
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

9.  Blood lead and haemoglobin in lead absorption.

Authors:  M K Williams
Journal:  Br J Ind Med       Date:  1966-04

10.  Pbrphyrin biosynthesis in erythrocytes. II. Enzymes converting gamma-aminolevulinic acid to coproporphyrinogen.

Authors:  S GRANICK; D MAUZERALL
Journal:  J Biol Chem       Date:  1958-06       Impact factor: 5.157

View more
  1 in total

1.  Comparative study of effects of lead on the activity of erythrocyte pyrimidine 5'-nucleotidase and delta-aminolevulinate dehydratase in vivo and in vitro.

Authors:  K Tomokuni; M Ogata
Journal:  Arch Toxicol       Date:  1980-09       Impact factor: 5.153

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.